An Open-label, Single Center Study Evaluating the Safety and Efficacy of Roflumilast Foam 0.3% in Subjects With Cutaneous Adverse Events Due to Checkpoint Inhibitors

Conditions

• Immune-related Dermatitis

Interventions

• DRUG: Roflumilast 0.3% topical foam

Sponsor

Massachusetts General Hospital